- $2.34bn
- $1.08bn
- $548.51m
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Orphan Drug Designation For Sovleplenib In Primary Immune Thrombocytopenia
HUTCHMED to Host Event on Recent Savolitinib Data
SANOVO Phase III Data at ESMO
SAFFRON Phase III Data ESMO & NEJM Publication
Kras: EGFR-Antibody licensing deal with GSK closes
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
UK Stocks-Factors to watch on September 29 (updated)
Submission of US NDA for ORPATHYS® plus TAGRISSO
UK Stocks-Factors to watch on September 29
China's HUTCHMED climbs as AstraZeneca applies for US cancer drug approval
Brief: Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso